The Dan O'Keefe SMFM Leadership Academy
The path to transformational leadership.
The Dan O’Keeffe SMFM Leadership Academy is designed to engage MFM subspecialists in a unique professional development experience that frames leadership as the ability to build relationships, cultivate excellence, and sustain energy for productive influence, agency, and motivation to enact positive change.
As a participant, you will engage with your peers and gain critical leadership knowledge and skills for today’s healthcare environment. The registration fee includes both in-person sessions, as well as five web-based sessions.
Session 1: October 8-10, 2021
Session 2: March 18-20, 2022
Where: Ritz-Carlton Hotel, Denver, CO
Course Faculty: Mike Foley, MD; Dan O'Keeffe, MD; and Idahlynn Karre, PhD
Registration Rates: The fee includes both in-person sessions and five web-based sessions; all course materials; as well as breakfast and lunch on both in-person sessions.
Members: $3,235
Non-Members: $4,325
To register and for more information, visit SMFM.org.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Prenatal SSRI or SNRI discontinuation not linked to adverse psychiatric outcomes
October 8th 2024In a recent study, similar rates of adverse psychiatric-related outcomes were reported among patients with discontinuation of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors vs those without discontinuation.
Read More
